#United States #New York #Securities Fraud #Rosen Law Firm #Applied Therapeutics

Investors’ Opportunity in Applied Therapeutics Class Action

Rosen Law Firm Announces Important Deadline
The Rosen Law Firm, a well-regarded global investor rights law practice, is reminding all purchasers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities to be aware of an impending lead plaintiff deadline on February 18, 2025. Individuals who acquired shares during the designated class period from January 3, 2024, to December 2, 2024, might be eligible for compensation without facing any out-of-pocket fees via a contingency fee framework.

Details on Joining the Class Action
If you have bought securities from Applied Therapeutics during the stipulated timeframe, you might qualify to be part of the class action lawsuit. To take action, interested parties can visit Rosen Law Firm's submission page. For further inquiries, Phillip Kim, Esq. can be contacted toll-free at 866-767-3653 or via email at [email protected]. A prior class action lawsuit has already been initiated, and those looking to represent fellow investors as lead plaintiff must file a motion with the court by the February deadline.

Why Choose Rosen Law Firm?
Rosen Law Firm serves a pivotal role in advocating for investor rights and emphasizes the selection of qualified counsel with proven success records. Many firms mention class actions but do not possess the equivalent experience or resources required. Rosen Law Firm has gained significant recognition for its high number of settlements in securities class actions, including one notable settlement against a Chinese company, which was the largest at the time. In 2019, the firm managed to recover over $438 million for its clients, demonstrating their efficacy in driving positive outcomes for investors.

Allegations Against Applied Therapeutics
The heart of the lawsuit revolves around claims that statements made during the class period were deceptive and materially misleading. Specifically, the lawsuit argues that Applied Therapeutics concealed critical details about its clinical trial protocols. The allegations suggest that the firm failed to comply with proper clinical standards, thus deteriorating the credibility of trial data and raising the risk of rejection by the FDA concerning a New Drug Application. Investors faced substantial losses once the genuine circumstances became public.

Important Considerations for Investors

• - No Class Certification Yet: It's crucial to note that a class hasn't been certified at this point. Until any such certification occurs, you are not legally represented unless you engage counsel individually.
• - Your Options: Investors can opt to remain uninvolved in the proceedings or choose to select their counsel if they prefer active participation in the lawsuit.
• - Potential Recovery: The process of becoming a lead plaintiff is not necessary for you to gain from any future recovery, ensuring that all investors can share in any potential results, regardless of their active role during this period.

Stay Updated: For updates and more information, follow Rosen Law Firm on LinkedIn, Twitter, or Facebook.

Conclusion
In conclusion, the upcoming deadline is a crucial moment for investors of Applied Therapeutics. Act now to ensure that your rights are represented. The Rosen Law Firm stands ready to assist and guide all potential claimants through this litigation process.